JAK2 Mutation Detection via Segmented Oligonucleotide Hybridization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting hematopoietic diseases such as myeloproliferative disorders, particularly those involving the JAK2 gene mutations, are not sufficiently accurate or reliable, especially in identifying specific mutations like JAK2 V617F, which are prevalent in conditions like polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.
Innovation Solution
A method for detecting the presence or absence of JAK2 mutations in biological samples using nucleic acid or polypeptide analysis, including amplification and sequencing techniques, to identify specific mutations like a2091t in nucleic acid and N533Y in polypeptide, which are associated with myeloproliferative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used for detecting JAK2 gene mutations, then the detection process is simpler, but the accuracy and reliability of identifying specific mutations like JAK2 V617F is insufficient
Solution Approach 1:
The patent segments the detection process into multiple specialized steps: nucleic acid extraction, PCR amplification of specific JAK2 exons, mutation-specific oligonucleotide hybridization, and detection. This segmentation allows each step to be optimized for its specific function, thereby improving overall detection accuracy while maintaining manageable complexity through modularization.
Solution Approach 2:
The patent introduces mutation-specific oligonucleotides as intermediaries that bind selectively to mutant JAK2 sequences. These oligonucleotide probes act as mediators between the target mutation and the detection system, enabling highly specific identification of mutations like V617F through controlled hybridization under stringent conditions.
2Reliability
If current detection methods are used, then the process is faster and simpler, but the ability to identify specific mutations associated with myeloproliferative diseases is insufficient
Solution Approach 1:
The patent employs preliminary action by designing and pre-synthesizing mutation-specific oligonucleotide probes for known JAK2 mutations (V617F, H674L, H674Q, H674R, H674W, H674Y). These probes are prepared in advance and can be directly applied to detect specific mutations, ensuring reliable identification while reducing detection time compared to developing new detection methods for each mutation.
Solution Approach 2:
The patent utilizes parameter changes in the hybridization conditions (temperature, salt concentration, pH) to optimize the binding specificity of oligonucleotide probes. By adjusting these parameters, the method achieves high reliability in distinguishing mutant from wild-type sequences, enabling accurate detection of specific JAK2 mutations associated with myeloproliferative diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate diagnosis and prognosis of myeloproliferative diseases by specifically identifying JAK2 mutations, improving the detection of conditions like polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis, and monitoring treatment efficacy.
Implementation Method 1
amplification and sequencing techniques
Implementation Method 2
amplification and sequencing techniques
Data Source
Figure 1(A)~1(C)
Figure 2
AI summary
The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.